Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients : The endocrinological effects of pretreatment with chlormadinone acetate

Journal of Medical Investigation

Volumn 46, Issue 1-2, 1999, Pages 55-58

  Yamamoto, Akihiro ^a   Sumiyoshi, Yoshiteru ^b   Miyake, Noriaki ^c   Yokozeki, Hideaki ^d   Kanayama, Hiro Omi ^e   Kagawa, Susumu ^e  

^a Kochi Takasu Hospital   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c Yashima General Hospital   (Japan)

^d TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Chlormadinone acetate; Disease flare; Luteinizing hormone releasing hormone analogue; Prostate cancer

Indexed keywords

ANTIANDROGEN; CHLORMADINONE ACETATE; GONADORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HORMONE BLOOD LEVEL; HUMAN; MALE; PROSTATE CANCER; TESTOSTERONE RELEASE;

ADMINISTRATION, ORAL; AGED; CHLORMADINONE ACETATE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GABA MODULATORS; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PROGESTERONE CONGENERS; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 0032714519     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Faure N, Lemay A, Laroche B, Robert G, Plante R, Jean C, Thabet M, Roy R, Fazekas ATA : Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. Prostate 4 : 601-624, 1983
2. Kahan A, Delrieu F, Amor B, Chiche R, Steg A : Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer. Lancet 1 : 971-972, 1984
3. Labrie F, Dupont A, Belanger A, Lachance R : Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 138 : 804-806, 1987
4. Schulze H, Senge T : Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 144 : 934-941, 1990
5. Yoshida K, Takeuchi S : Pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing -hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate. Eur Urol 27 : 187-191, 1995
6. Shimizu T, Shibata Y, Jinbo H, Satoh J, Yamanaka H : Estramustine phosphate for presrventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy. Eur Urol 27 : 192-195, 1995
7. Japanese Urological Association and the Japanese Pathological Society : General Rules for Clinical Pathological Studies on Prostatic Cancer, ed 2. Kanehara Shuppan, Tokyo, 1992
8. Shida K : Fundamental and clinical study on anti-androgen-androgen dependency of prostatic tumors and clinical application of anti-androgens. Asian Med J 24 : 747-776, 1981
9. Nishimura R, Shida K : Antiandrogenic therapy for the treatment of early stage prostatic cancer. Prostate 1 (suppl) : 27-34, 1981
10. Prostate Cancer Trialists' Collaborative Group : Maximum androgen blockade in advanced prostate cancer : an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 346 : 265-269, 1995
11. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD : Maximum androgen blockade in advanced prostate cancer : A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49 : 71-78, 1997